Advocating for Demonstration of Disease Modification-Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?

Vincent Planche; Nicolas Villain

doi:10.1001/jamaneurol.2023.0815

Advocating for Demonstration of Disease Modification-Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?

JAMA Neurol. 2023 Jul 1;80(7):659-660. doi: 10.1001/jamaneurol.2023.0815.

Authors

Vincent Planche^{1

2}, Nicolas Villain^{3

4}

Affiliations

¹ Centre National de la Recherche Scientifique, Université de Bordeaux, Institut des Maladies Neurodégéneratives, Bordeaux, France.
² Centre Mémoire Ressources Recherches, Pôle de Neurosciences Cliniques, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
³ AP-HP.Sorbonne Université, Institut de la Mémoire et de la Maladie d'Alzheimer, Département de Neurologie, Hôpital Pitié-Salpêtrière, Paris, France.
⁴ Sorbonne Université, Institut national de la Santé et de la Recherche Medical (INSERM) U1127, Centre National de la Recherche Scientifique (CNRS) 7225, Institut du Cerveau-ICM, Paris, France.

PMID: 37093582
DOI: 10.1001/jamaneurol.2023.0815

No abstract available

Plain language summary

This Viewpoint discusses the benefits of clinical trials with a delayed-start design and analysis of downstream biomarkers to examine whether antimyeloid immunotherapy changes the course of early Alzheimer disease.

MeSH terms

Alzheimer Disease* / drug therapy
Biomarkers
Clinical Trials as Topic
Humans
Research Design

Substances

Biomarkers